A Trio of New Hepatitis C Drugs Being Tested
July 13, 2011
Achillion Pharmaceuticals Inc. (ACHN) Begins Dosing for Hepatitis C Treatment, Prepares for Clinical Milestones
By QualityStocks | July 12, 2011
Achillion Pharmaceuticals Inc., focused on developing treatments for infectious disease, today announced it has begun dosing in a phase 1 clinical trial of ACH-2684 for the treatment of chronic hepatitis C virus (HCV) infection.
The study is a randomized, double-blind, placebo-controlled trial designed to determine the safety, tolerability, pharmacokinetic profile and antiviral activity of ACH-2684, and will include up to 78 healthy volunteers and up to 40 HCV-infected patients.
“This first-in-human clinical trial will be instrumental in establishing the safety profile of ACH-2684 in humans,” Elizabeth A. Olek, D.O., vice president and chief medical officer of Achillion stated in the press release. “It will also provide Achillion with important preliminary efficacy data against HCV genotypes 1 and 3, and help us to select doses for subsequent clinical development.”
Continue reading this entire article:
Factors that Raise the Risk of Hepatitis C Relapse
The Hepatitis A Virus Loves Summertime